Stereotactic body radiotherapy for early lung cancer

Yoshiyuki Shioyama, Akira Matsunobu, Makoto Shinoto, Katsumasa Nakamura, Tomonari Sasaki, Ohga Saiji, Tadamasa Yoshitake, Kaori Asai, Hiroshi Honda

研究成果: ジャーナルへの寄稿評論記事

抄録

Although the standard treatment method for stage I non-small cell lung cancer is surgery (lobectomy), many patients are inoperable due to age andor complications. Radiotherapy is often performed in inoperable patients; however, the results of conventional fractionated radiotherapy are not satisfactory. In recent years, the high efficacy and safety of stereotactic body radiotherapy (SBRT), which can be used to deliver a targeted high dose to the tumor while minimizing effects on adjacent normal tissues, have been demonstrated, and SBRT has become a standard treatment for medically inoperable patients with stage I non-small cell lung cancer in place of conventional fractionated radiotherapy. Although the high efficacy of SBRT has been reported in operable patients, the equivalence of the treatment effect compared with surgery has not been confirmed in randomized controlled trials, and a consensus regarding the optimal treatment has not been reached. In elderly subjects or marginally operable patients in whom performing lobectomy is difficult although limited surgery (segmentectomy or wedge resection) is possible, SBRT is a reasonable and less invasive treatment option with expected results equivalent to surgical intervention. However, there is not yet sufficient evidence to confirm the efficacy and safety of this treatment over long-term follow-up, and several issues, including the optimal dose and fractionation, use of adjuvant chemotherapy, diagnosis of recurrence and effectiveness of salvage treatment after recurrence, remain to be addressed.

元の言語英語
ページ(範囲)910-916
ページ数7
ジャーナルJapanese Journal of Lung Cancer
54
発行部数7
DOI
出版物ステータス出版済み - 12 20 2014

Fingerprint

Radiosurgery
Lung Neoplasms
Radiotherapy
Non-Small Cell Lung Carcinoma
Dose Fractionation
Therapeutics
Safety
Recurrence
Salvage Therapy
Segmental Mastectomy
Adjuvant Chemotherapy
Randomized Controlled Trials
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

これを引用

Shioyama, Y., Matsunobu, A., Shinoto, M., Nakamura, K., Sasaki, T., Saiji, O., ... Honda, H. (2014). Stereotactic body radiotherapy for early lung cancer. Japanese Journal of Lung Cancer, 54(7), 910-916. https://doi.org/10.2482/haigan.54.910

Stereotactic body radiotherapy for early lung cancer. / Shioyama, Yoshiyuki; Matsunobu, Akira; Shinoto, Makoto; Nakamura, Katsumasa; Sasaki, Tomonari; Saiji, Ohga; Yoshitake, Tadamasa; Asai, Kaori; Honda, Hiroshi.

:: Japanese Journal of Lung Cancer, 巻 54, 番号 7, 20.12.2014, p. 910-916.

研究成果: ジャーナルへの寄稿評論記事

Shioyama, Yoshiyuki ; Matsunobu, Akira ; Shinoto, Makoto ; Nakamura, Katsumasa ; Sasaki, Tomonari ; Saiji, Ohga ; Yoshitake, Tadamasa ; Asai, Kaori ; Honda, Hiroshi. / Stereotactic body radiotherapy for early lung cancer. :: Japanese Journal of Lung Cancer. 2014 ; 巻 54, 番号 7. pp. 910-916.
@article{650bb6064f4843ed9438d033e7aba6d1,
title = "Stereotactic body radiotherapy for early lung cancer",
abstract = "Although the standard treatment method for stage I non-small cell lung cancer is surgery (lobectomy), many patients are inoperable due to age andor complications. Radiotherapy is often performed in inoperable patients; however, the results of conventional fractionated radiotherapy are not satisfactory. In recent years, the high efficacy and safety of stereotactic body radiotherapy (SBRT), which can be used to deliver a targeted high dose to the tumor while minimizing effects on adjacent normal tissues, have been demonstrated, and SBRT has become a standard treatment for medically inoperable patients with stage I non-small cell lung cancer in place of conventional fractionated radiotherapy. Although the high efficacy of SBRT has been reported in operable patients, the equivalence of the treatment effect compared with surgery has not been confirmed in randomized controlled trials, and a consensus regarding the optimal treatment has not been reached. In elderly subjects or marginally operable patients in whom performing lobectomy is difficult although limited surgery (segmentectomy or wedge resection) is possible, SBRT is a reasonable and less invasive treatment option with expected results equivalent to surgical intervention. However, there is not yet sufficient evidence to confirm the efficacy and safety of this treatment over long-term follow-up, and several issues, including the optimal dose and fractionation, use of adjuvant chemotherapy, diagnosis of recurrence and effectiveness of salvage treatment after recurrence, remain to be addressed.",
author = "Yoshiyuki Shioyama and Akira Matsunobu and Makoto Shinoto and Katsumasa Nakamura and Tomonari Sasaki and Ohga Saiji and Tadamasa Yoshitake and Kaori Asai and Hiroshi Honda",
year = "2014",
month = "12",
day = "20",
doi = "10.2482/haigan.54.910",
language = "English",
volume = "54",
pages = "910--916",
journal = "Japanese Journal of Lung Cancer",
issn = "0386-9628",
publisher = "Japan Lung Cancer Society",
number = "7",

}

TY - JOUR

T1 - Stereotactic body radiotherapy for early lung cancer

AU - Shioyama, Yoshiyuki

AU - Matsunobu, Akira

AU - Shinoto, Makoto

AU - Nakamura, Katsumasa

AU - Sasaki, Tomonari

AU - Saiji, Ohga

AU - Yoshitake, Tadamasa

AU - Asai, Kaori

AU - Honda, Hiroshi

PY - 2014/12/20

Y1 - 2014/12/20

N2 - Although the standard treatment method for stage I non-small cell lung cancer is surgery (lobectomy), many patients are inoperable due to age andor complications. Radiotherapy is often performed in inoperable patients; however, the results of conventional fractionated radiotherapy are not satisfactory. In recent years, the high efficacy and safety of stereotactic body radiotherapy (SBRT), which can be used to deliver a targeted high dose to the tumor while minimizing effects on adjacent normal tissues, have been demonstrated, and SBRT has become a standard treatment for medically inoperable patients with stage I non-small cell lung cancer in place of conventional fractionated radiotherapy. Although the high efficacy of SBRT has been reported in operable patients, the equivalence of the treatment effect compared with surgery has not been confirmed in randomized controlled trials, and a consensus regarding the optimal treatment has not been reached. In elderly subjects or marginally operable patients in whom performing lobectomy is difficult although limited surgery (segmentectomy or wedge resection) is possible, SBRT is a reasonable and less invasive treatment option with expected results equivalent to surgical intervention. However, there is not yet sufficient evidence to confirm the efficacy and safety of this treatment over long-term follow-up, and several issues, including the optimal dose and fractionation, use of adjuvant chemotherapy, diagnosis of recurrence and effectiveness of salvage treatment after recurrence, remain to be addressed.

AB - Although the standard treatment method for stage I non-small cell lung cancer is surgery (lobectomy), many patients are inoperable due to age andor complications. Radiotherapy is often performed in inoperable patients; however, the results of conventional fractionated radiotherapy are not satisfactory. In recent years, the high efficacy and safety of stereotactic body radiotherapy (SBRT), which can be used to deliver a targeted high dose to the tumor while minimizing effects on adjacent normal tissues, have been demonstrated, and SBRT has become a standard treatment for medically inoperable patients with stage I non-small cell lung cancer in place of conventional fractionated radiotherapy. Although the high efficacy of SBRT has been reported in operable patients, the equivalence of the treatment effect compared with surgery has not been confirmed in randomized controlled trials, and a consensus regarding the optimal treatment has not been reached. In elderly subjects or marginally operable patients in whom performing lobectomy is difficult although limited surgery (segmentectomy or wedge resection) is possible, SBRT is a reasonable and less invasive treatment option with expected results equivalent to surgical intervention. However, there is not yet sufficient evidence to confirm the efficacy and safety of this treatment over long-term follow-up, and several issues, including the optimal dose and fractionation, use of adjuvant chemotherapy, diagnosis of recurrence and effectiveness of salvage treatment after recurrence, remain to be addressed.

UR - http://www.scopus.com/inward/record.url?scp=84923819125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923819125&partnerID=8YFLogxK

U2 - 10.2482/haigan.54.910

DO - 10.2482/haigan.54.910

M3 - Review article

AN - SCOPUS:84923819125

VL - 54

SP - 910

EP - 916

JO - Japanese Journal of Lung Cancer

JF - Japanese Journal of Lung Cancer

SN - 0386-9628

IS - 7

ER -